Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?

Executive Summary

Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.

Advertisement

Related Content

First Draft FDA User Fee Bill Is Squeaky Clean
A Hiring Freeze By A Different Name: OMB Wants Agency 'Workforce Reduction' Plans
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed
The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity
Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
Trump Slams FDA Regulations In Joint Session Of Congress
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Off-Label Communication: When Does It Align With Approved Labeling?
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up

Topics

Advertisement
UsernamePublicRestriction

Register

PS120465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel